<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="754">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05151341</url>
  </required_header>
  <id_info>
    <org_study_id>2021-A01054-37</org_study_id>
    <nct_id>NCT05151341</nct_id>
  </id_info>
  <brief_title>Study of Combined VisioCyt Test and FGFR3 Mutations on a Urinary Sample to Diagnose Bladder Tumors</brief_title>
  <acronym>URODX-FGFR3</acronym>
  <official_title>Evaluation of a Urine Analysis Combining VisioCyt® Automated Cytology and FGFR3 Mutations for the Detection of Bladder Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Institut de Cancérologie de Lorraine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitadx</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Institut de Cancérologie de Lorraine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a case-control, propsective and muticentric clinical trial, which aim to&#xD;
      compare the specificity and sensibility of VisioCyt urinary cytological test combined with&#xD;
      FGFR3 mutation detection test to VisioCyt urinary cyological test on its own to detect&#xD;
      bladder cancer.&#xD;
&#xD;
      The case are patient in whom newly diagnosed, or recurring /progressing bladder cancer is&#xD;
      strongly suspected after initial fibroscopy.&#xD;
&#xD;
      The control are patient attending or hospitalized for urolithiasis, urinary infections,&#xD;
      urinary superior excretory stones or with non suspect urinary symptomatology.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 1, 2021</start_date>
  <completion_date type="Anticipated">May 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">May 1, 2024</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Specificity</measure>
    <time_frame>at inclusion</time_frame>
    <description>Specificity comparaison between Visiocyt test + FGFR3 analysis and FGFR3 analysis on its own</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Sensibility of the 4 different tests</measure>
    <time_frame>at inclusion</time_frame>
    <description>Sensibility Comparaison between :&#xD;
Visiocyt test + FGFR3 analysis&#xD;
FGFR3 analysis on its own&#xD;
Visiocyt test on its own&#xD;
Standard cytology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Specificity of the 4 different tests</measure>
    <time_frame>at inclusion</time_frame>
    <description>Specificity Comparaison between :&#xD;
Visiocyt test + FGFR3 analysis&#xD;
FGFR3 analysis on its own&#xD;
Visiocyt test on its own&#xD;
Standard cytology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Positive predictive value of the 4 different tests</measure>
    <time_frame>at inclusion</time_frame>
    <description>Positive predictive value between :&#xD;
Visiocyt test + FGFR3 analysis&#xD;
FGFR3 analysis on its own&#xD;
Visiocyt test on its own&#xD;
Standard cytology</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Negative predictive value of the 4 different tests</measure>
    <time_frame>at inclusion</time_frame>
    <description>Negative predictive value between :&#xD;
Visiocyt test + FGFR3 analysis&#xD;
FGFR3 analysis on its own&#xD;
Visiocyt test on its own&#xD;
Standard cytology</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">190</enrollment>
  <condition>Bladder Cancer</condition>
  <arm_group>
    <arm_group_label>Case</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient in whom newly diagnosed, or recurring / progressing bladder cancer is strongly suspected after initial fibroscopy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patient attending or hospitalized for urolithiasis, urinary infections, superior excretory stones or with non suspect urinary symptomatology</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>Urine collection (150ml)</intervention_name>
    <description>Urine collection will be tacken at inclusion. The sample will be thereafter separate into three to realise different analyzes (standard cytology, Visiocyt test, FGFR3 analysis)</description>
    <arm_group_label>Case</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Blood sample (20 ml)</intervention_name>
    <description>Blood sample will be tacken at inclusion, ONLY for &quot;case&quot; patients that agreed upon this. This sample will be addition to the collection for further research.</description>
    <arm_group_label>Case</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA&#xD;
&#xD;
        BOTH GROUPS&#xD;
&#xD;
          -  M/F&#xD;
&#xD;
          -  Patient agrees to follow study protocol and is able to follow study procedures&#xD;
&#xD;
          -  Patient signed, dated and understood consent form&#xD;
&#xD;
          -  Patient has a social security scheme&#xD;
&#xD;
        CASE GROUP&#xD;
&#xD;
          -  Patient is 18 or older&#xD;
&#xD;
          -  Patient for whom a bladder cancer recently diagnosed, or backsliding/progression is&#xD;
             heavily suspected after the initial fibroscopy&#xD;
&#xD;
          -  Patient who hasn't started systemic/oral/radiotheurapeutic pelvic treatment for&#xD;
             his/her tumor&#xD;
&#xD;
        CONTROL GROUP&#xD;
&#xD;
          -  Patient between 18 and 45 y/o&#xD;
&#xD;
          -  Patient not suspected of having any bladder cancer&#xD;
&#xD;
          -  Patient attending or hospitalized for urolithiasis, urinary infections, superior&#xD;
             excretory stones or with non suspect urinary symptomatology&#xD;
&#xD;
          -  Patient who hasn't been exposed to bladder carcinogens (tobacco, industrial carcinogen&#xD;
             (ex: coal tar, tar/coal oils, coal pitch and burning coal soot), urinary bilharzia,&#xD;
             chemotherapy exposition (cyclophosphamid)&#xD;
&#xD;
          -  Patient that had a negative cytopathological exploration of the excretory urinary&#xD;
             route OR/AND iconography (pelvic echography, pelvic scanner) OR/AND endoscopy with&#xD;
             prior urinary sample&#xD;
&#xD;
          -  Patient unscathed of any cancer that might interact with bladder cancer : uterine&#xD;
             cancer, prostate cancer, rectal cancer, and metastasis from other cancer or&#xD;
             non-urologic tumor invading the bladder&#xD;
&#xD;
        EXCLUSION CRITERIA BOTH GROUPS&#xD;
&#xD;
          -  Non-treated current urinary infection&#xD;
&#xD;
          -  Patient with another pelvic cancer&#xD;
&#xD;
          -  Bladder cancer outside of urothelial carcinoma&#xD;
&#xD;
          -  Associated carcinoma of the high urinary apparatus&#xD;
&#xD;
          -  Patient that received renal transplantation (BK virus)&#xD;
&#xD;
          -  Patient that received pelvis radiotherapy (related to prostatic cancer, gynecologic&#xD;
             cancer or pelvic digestive cancer)&#xD;
&#xD;
          -  Patient having a JJ catheter&#xD;
&#xD;
          -  Refused to signed consent&#xD;
&#xD;
          -  Pregnant, susceptible to be, or breast-feeding women&#xD;
&#xD;
          -  Person Under guardianship&#xD;
&#xD;
          -  Impossibility to submit to medical monitoring because of geographic, social, or mental&#xD;
             issues&#xD;
&#xD;
        CASE GROUP • Under 18y/o&#xD;
&#xD;
        CONTROL GROUP&#xD;
&#xD;
        • Under 18y/o or above 45 y/o&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eschwège Pascal, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Institut de Cancérologie de Lorraine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MERLIN Jean-Louis, PU PH</last_name>
    <phone>03 83 65 60 62</phone>
    <phone_ext>0033</phone_ext>
    <email>jl.merlin@nancy.unicancer.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>HERMAN Marie Aude</last_name>
    <phone>03 83 53 86 68</phone>
    <phone_ext>0033</phone_ext>
    <email>m.herman@nancy.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <zip>54519</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Eschwège Pascal, MD, PhD</last_name>
      <phone>03 83 59 84 17</phone>
      <email>p.eschwege@nancy.unicancer.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2021</verification_date>
  <study_first_submitted>December 1, 2021</study_first_submitted>
  <study_first_submitted_qc>December 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">December 9, 2021</study_first_posted>
  <last_update_submitted>December 1, 2021</last_update_submitted>
  <last_update_submitted_qc>December 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>FGFR3</keyword>
  <keyword>VisioCyt</keyword>
  <keyword>Bladder Tumor</keyword>
  <keyword>Cancer</keyword>
  <keyword>FGFR3 Mutation</keyword>
  <keyword>Diagnosis</keyword>
  <keyword>Cytoloogy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

